Denali Therapeutics (DNLI) Common Equity (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Common Equity data on file, last reported at $926.1 million in Q1 2026.

• Common Equity for Q1 2026 came in at $926.1 million, down 17.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $926.1 million (down 17.51% YoY), and the FY2025 annual result was $1.0 billion, down 17.56% from the prior year.
• Common Equity eased to $926.1 million in Q1 2026 per DNLI's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Common Equity peaked at $1.5 billion in Q1 2024 and troughed at $811.3 million in Q3 2022.
• A 5-year average of $1.1 billion and a median of $1.0 billion in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity surged 50.56% in 2024, then declined 29.75% in 2025.
• A 5-year view of Common Equity shows it stood at $1.0 billion in 2022, then slipped by 1.1% to $1.0 billion in 2023, then gained by 19.28% to $1.2 billion in 2024, then retreated by 17.56% to $1.0 billion in 2025, then fell by 8.65% to $926.1 million in 2026.
• Business Quant data shows DNLI's Common Equity at $926.1 million in Q1 2026, $1.0 billion in Q4 2025, and $926.2 million in Q3 2025.